In the era of targeted therapy for cancer, molecular diagnosis of particular genetic markers in tumours enables a more individualised treatment of patients, as was recently shown for KRAS mutation status and response rate to anti-EGFR therapy in CRC (Pichler et al, 2009). The gene discussed is KRAS; the disease is neoplasm.